Overview
Location
France
Total raised
$14.03M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 10, 2026 | 4Moving Biotech Closes €12 Million Financing To Push Knee Osteoarthritis Drug Toward Phase 2a Proof Of Concept | 4Moving Biotech (4MB), a clinical-stage biotechnology company spun out of 4P-Pharma, said it has closed a €12 million financing to advance its lead disease-modifying osteoarthritis drug (DMOAD) program for knee osteoarthritis, a condition t... |
| Apr 8, 2025 | 4Moving Biotech: €7.6 Million France 2030 Grant Secured | 4Moving Biotech (4MB), a spin-off of 4P-Pharma that is developing the first potential disease-modifying drug (DMOAD) for knee osteoarthritis, announced that it has been awarded €7.6 million in funding under the France 2030 plan to accelerat... |
| 4Moving Biotech | “Home | 4Moving” |
Reviews 0
FAQ about 4Moving
How much funding has 4Moving raised?
4Moving has raised $14.03M in total across 1 funding round.
What has the press written about 4Moving?
Parsers VC has collected 4 articles mentioning 4Moving, among them “4Moving Biotech Closes €12 Million Financing To Push Knee Osteoarthritis Drug Toward Phase 2a Proof Of Concept” (Feb 10, 2026) and “4Moving Biotech: €7.6 Million France 2030 Grant Secured” (Apr 8, 2025).
Is 4Moving still active?
Yes, 4Moving is active; its latest activity on Parsers VC dates from Feb 10, 2026.